Everest Medicines | BiotechTV

top of page

Everest Medicines' CFO Ian Woo, and an expert in China biotech, describes the company's and the country's evolution from in-licensing assets from the West to developing its own innovative medicines

He discusses key assets Everest has in-licensed, including NEFCON and etrasimod, and describes the innovative work Everest is doing in...

Sep 9

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Everest Medicines' CFO Ian Woo, and an expert in China biotech, describes the company's and the country's evolution from in-licensing assets from the West to developing its own innovative medicines

Follow BiotechTV

Sponsors

Sponsor Spotlight